<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32336">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02685709</url>
  </required_header>
  <id_info>
    <org_study_id>OOC-ACM-302</org_study_id>
    <secondary_id>2015-002854-11</secondary_id>
    <nct_id>NCT02685709</nct_id>
  </id_info>
  <brief_title>Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly</brief_title>
  <acronym>MPOWERED</acronym>
  <official_title>A Phase 3, Randomized, Active Controlled Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated With Octreotide Capsules vs. Parenteral Somatostatin Receptor Ligands</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiasma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiasma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Octreotide capsule is a novel, orally-administered formulation of the commercially-available
      injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated
      sustained biochemical response up to 13 months in patients with acromegaly previously
      managed with somatostatin analog injections (ref).

      The purpose of this study is to compare the efficacy safety and patient reported outcomes
      between oral octreotide capsules and injectable somatostatin analogs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a phase 3, randomized, open-label, active controlled, multicenter study to
      evaluate maintenance of response, safety and patient reported outcomes (PROs) in acromegaly
      patients treated with octreotide capsules and in patients treated with SOC parenteral SRLs,
      who previously tolerated and demonstrated biochemical control on both treatments.

      The core study will consist of three phases: a Screening phase, Run-in phase and a
      Randomized Controlled Treatment Phase (RCT).

      Eligible patients who are biochemically controlled on parenteral SRLs will be switched to
      octreotide capsules for a 26-week Run-in phase. During this phase the effective dose for
      each patient will be determined through dose titration.

      Patients whose acromegaly is been controlled biochemically on octreotide capsules at the end
      of the Run-in Phase will enter a 36-week open-label Randomized Controlled Treatment Phase,
      where they will be randomized to continue on octreotide capsules or switch back to their
      injectable SRL treatment (as received prior to Screening).

      Following the completion of the core study (Screening, Run-in and RCT phases), eligible
      patients will be offered to enter the Study Extension phase and receive octreotide capsules
      until product marketing or study termination.

      A Sub-study, in selected sites, would allow patients with in-adequate biochemical control on
      octreotide capsules during the Run-in Phase to enter a Combination phase and receive
      co-administration of octreotide capsules with cabergoline tablets for a total of 36 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IGF-1 Time Weighted Average (TWA), during the RCT phase</measure>
    <time_frame>62 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in acromegaly symptoms</measure>
    <time_frame>62 weeks</time_frame>
    <description>Acromegaly Index of Severity Score (AIS) - Headache, Swelling of extremities, Joint pain, Sweating and Fatigue, assessed by severity (0-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical and biochemical response</measure>
    <time_frame>62 weeks</time_frame>
    <description>Biochemical response - IGF-1 TWA Clinical response - maintained or improved acromegaly symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
    <time_frame>62 weeks</time_frame>
    <description>Acro-TSQ - newly developed and validated patient reported outcome questionnaire</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Run-in phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral octreotide capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RCT phase - Oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral octreotide capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RCT phase - Injectables</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injectable somatostatin analogs (octreotide or lanreotide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination phase (sub-study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Octreotide capsules plus cabergoline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide capsules</intervention_name>
    <description>Octreotide capsules 40mg/day, 60mg/day, 80mg/day</description>
    <arm_group_label>Run-in phase</arm_group_label>
    <arm_group_label>RCT phase - Oral</arm_group_label>
    <arm_group_label>Combination phase (sub-study)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injectable Somatostatin Analogs (octreotide or lanreotide)</intervention_name>
    <description>Octreotide - 10, 20, 30mg. Lanreotide 60,90, 120mg.</description>
    <arm_group_label>RCT phase - Injectables</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabergoline</intervention_name>
    <description>Cabergoline - 3.5mg/week</description>
    <arm_group_label>Combination phase (sub-study)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of acromegaly

          -  Treatment with Somatostatin analogs injections (octreotide or lanreotide) for at
             least 6 months

          -  Biochemical control (IGF -1 &lt; 1.3 x ULN and GH &lt; 2.5ng/mL)

        Exclusion Criteria:

          -  Injections of long-acting somatostatin analogs, at a dosing interval &gt; 8 weeks.

          -  Pituitary radiotherapy within 5 years

          -  Pituitary surgery within six months

          -  Patients who previously participated in CH-ACM-01 study

          -  Any clinically significant uncontrolled concomitant disease

          -  Symptomatic cholelithiasis

          -  Previous treatment with:

          -  Pegvisomant, within 12 weeks

          -  Dopamine agonists, within 6 weeks

          -  Pasireotide, within 12 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Fleseriu, M.D., FACE</last_name>
    <role>Study Chair</role>
    <affiliation>Northwest Pituitary Center, Oregon Health &amp; Science University , Portland, OR, USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Engage Health</last_name>
    <phone>+1-855-676-9733</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kentress Davison</last_name>
      <phone>205-934-4112</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keck Medical Center of University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Carmichael, MD</last_name>
      <email>John.Carmichael@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Ortega, MD</last_name>
      <phone>310-423-0022</phone>
      <email>Alicia.Ortega@cshs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Katznelson, MD</last_name>
      <email>katznels@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Kerr, MD</last_name>
      <phone>720-848-5146</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilee Wehunt</last_name>
      <phone>404-778-3746</phone>
      <email>emorga9@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gregory Johnstone, MSCM</last_name>
      <phone>404-778-7673</phone>
      <email>gpjohns@emory.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daphne Adelman, BSN, MBA</last_name>
      <phone>312-908-9002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>John H. Stroger, Jr. Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystyna Gielniewski</last_name>
      <phone>312-864-6144</phone>
      <email>kgielniewski@cookcountyhhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oyinkansola K Kusemiju</last_name>
      <phone>410-955-2812</phone>
      <email>okusemi1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Pulaski-Liebert</last_name>
      <phone>617-726-7473</phone>
      <email>kpulaski@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci Bell, RN</last_name>
      <phone>314-747-5371</phone>
      <email>Bell@wusl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palm Research Center, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Rutgers - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halina Malveaux</last_name>
      <phone>732-418-8483</phone>
      <email>malveaha@rwjms.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Reyes-Vidal</last_name>
      <phone>212-305-4921</phone>
      <email>csr52@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Howell, LPN</last_name>
      <phone>614-688-3785</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Intekhab Ahmed, MD</last_name>
      <phone>215-955-1925</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allegheny Endocrinology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenn Cisar, BA</last_name>
      <phone>412-359-6538</phone>
      <email>jcisar@aghendo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midstate Endocrinology Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randy Jerkins, Pharm.D.</last_name>
      <phone>615-329-5029</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Samson, MD, PhD</last_name>
      <phone>713-798-3076</phone>
      <email>ssamson@bcm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abhishek Kansara, MD</last_name>
      <phone>713-441-3246</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin Klinische Abteilung für Endokrinologie und Diabetologie</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Obermayer-Pietsch, MD</last_name>
      <phone>0114331638512383</phone>
      <email>barbara.obermayer@medunigraz.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anton Luger, MD, PhD</last_name>
      <phone>+ 43 14 040043100</phone>
      <email>anton.luger@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Raverot, MD, PhD</last_name>
      <phone>+ 33 4 72 11 93 25</phone>
      <email>gerald.raverot@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre APHP</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillipe Chanson, MD, PhD</last_name>
      <phone>+ 33 1 45 21 37 08</phone>
      <email>Philippe.chanson@bct.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis für Endokrinologie und Diabetologie Dr M Droste</name>
      <address>
        <city>Oldenburg</city>
        <zip>26122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Droste, MD</last_name>
      <phone>+49 44 12184615</phone>
      <email>studienzentrum@endokrin-ol.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Egeszsegugyi Kozpont</name>
      <address>
        <city>Budapest</city>
        <zip>H-1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laszlo Kovacs, MD</last_name>
      <phone>+36 20 563 9275</phone>
      <email>kovlac5@freemail.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pecs</name>
      <address>
        <city>Pecs</city>
        <zip>H-7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emese Mezosi, MD, PhD</last_name>
      <phone>+ 36 72 536165</phone>
      <email>mezosi.emese@pte.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem, I. Belgyógyászati Klinika</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsuzsanna Valkusz, MD</last_name>
      <email>valkusz.zsuzsanna@med.u-szeged.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico di Monserrato U.O.C. Endocrinologia e Diabetologia</name>
      <address>
        <city>Monserrato</city>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Mariotti, MD</last_name>
      <phone>+ 39 07 051096517</phone>
      <email>s.mariotti@unica.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università di Pisa Dipartimento di Medicina Clinica e Sperimentale</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fausto Bogazzi, MD, PhD</last_name>
      <phone>+39 050997348</phone>
      <email>fausto.bogazzi@med.unipi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli Università Cattolica del S.Cuore S.C. Endocrinologia e Malattie del Metabolismo</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura De Marinis, MD</last_name>
      <phone>+ 39 06 30156629</phone>
      <email>laurademarinis@yahoo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of LUHS Kauno Klinikos</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robertas Knispelis, MD</last_name>
      <phone>+370 6 869 9352</phone>
      <email>robertas.knispelis@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vaidotas Urbanavicius Individuali Imonė</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-10207</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaidotas Urbanavicius, MD, PhD</last_name>
      <phone>+370 5 236 5189</phone>
    </contact>
    <contact_backup>
      <email>vaidotas.urbanavicius@santa.lt</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu, Klinika Endokrynologii, Diabetologii i Leczenia Izotopami</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Bolanowski, MD, PhD</last_name>
      <phone>+ 48 71 7842546</phone>
      <email>marek.bolanowski@umed.wroc.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sechenov Moscow First State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119881</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Pavlova, PhD</last_name>
      <phone>+7 916 678 66 79</phone>
      <email>mgp.med@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Atlas&quot; Medical Center</name>
      <address>
        <city>Moscow</city>
        <zip>121170</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yury Poteshkin, MD, PhD</last_name>
      <phone>(7495) 212-0888</phone>
      <email>yuriy.poteshkin@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vladimirsky Moscow Regional Research Clinical Institute</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Dreval, PhD</last_name>
      <phone>+7 495 681 1308</phone>
      <email>dreval@diabet.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;V. A. Almazov Federal North-West Medical Research Centre&quot; of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194156</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Grineva, MD, PhD</last_name>
      <email>grineva_e@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia, Clinic for Endocrinology Diabetes and Metabolic Diseases</name>
      <address>
        <city>Belgrade</city>
        <zip>11 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Djuro Macut, MD, PhD</last_name>
      <email>djmacut@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Ribera</name>
      <address>
        <city>Alzira</city>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Fajardo, MD, PhD</last_name>
      <phone>+34 96 245 85 80</phone>
      <email>CfajardoO@hospital-ribera.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Puig-Domingo, MD, PhD</last_name>
      <phone>+34 93 497 88 60</phone>
      <email>mpuigd@igtp.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Casanueva Freijo, MD</last_name>
      <email>felipe.casanueva@usc.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Ayuk, MD, MRCP</last_name>
      <phone>+44121 371 6937</phone>
      <email>john.ayuk@uhb.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospitals NHS Foundation Trust, Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Ray, FRCP, PhD</last_name>
      <email>david.w.ray@manchester.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Debono, MD, PhD</last_name>
      <email>m.debono@sheffield.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.chiasmapharma.com</url>
    <description>Click here for more information about Chiasma</description>
  </link>
  <link>
    <url>http://www.mpoweredtrial.com</url>
    <description>Click here for more information about the study</description>
  </link>
  <reference>
    <citation>Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, Glaser B, Goth M, Greenman Y, Trainer P, Mezosi E, Shimon I, Giustina A, Korbonits M, Bronstein MD, Kleinberg D, Teichman S, Gliko-Kabir I, Mamluk R, Haviv A, Strasburger C. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab. 2015 Apr;100(4):1699-708. doi: 10.1210/jc.2014-4113. Epub 2015 Feb 9.</citation>
    <PMID>25664604</PMID>
  </reference>
  <reference>
    <citation>Melmed S. New therapeutic agents for acromegaly. Nat Rev Endocrinol. 2016 Feb;12(2):90-8. doi: 10.1038/nrendo.2015.196. Epub 2015 Nov 27. Review.</citation>
    <PMID>26610414</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 2, 2017</lastchanged_date>
  <firstreceived_date>January 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Octreotide Capsules</keyword>
  <keyword>Acromegaly</keyword>
  <keyword>Somatostatin</keyword>
  <keyword>Mpowered</keyword>
  <keyword>OOC-ACM-302</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Somatostatin</mesh_term>
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Cabergoline</mesh_term>
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
